17 results on '"Vanakesa, T."'
Search Results
2. 1269P Machine learning model for predicting lung cancer recurrence after surgical treatment: A retrospective study using NLST and European hospital data
3. P2.16-51 Nationwide Trends in Surgical Treatment of Lung Cancer in Estonia, 2000−2015
4. PUB054 Pathological Discrepancies in the Diagnosis of Thymic Malignancies: The Tallinn-Lyon Experience
5. Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)
6. P-163 * IMPACT OF ROUTINE PREOPERATIVE PET-CT (VERSUS CT) ON DEVELOPMENT OF POSTOPERATIVE DISTANT METASTASES IN SURGICALLY TREATED NON-SMALL-CELL LUNG CANCER PATIENTS
7. 72PD LOBECTOMY IN COMBINATION WITH RADICAL LYMPHADENECTOMY IS THE MOST FREQUENT SURGICAL INTERVENTION PERFORMED IN PATIENTS RANDOMIZED IN MAGRIT TRIAL EVALUATING MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT IN STAGE IB IIIA NSCLC
8. High Efficiency of Cryobiopsy in Diagnosing of Lung Cancer.
9. 6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic
10. 1173O - Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)
11. Neoadjuvant chemotherapy with Taxol and Carboplatina in combined stage IB–IIIA non-small cell lung cancer (NSCLC) treatment
12. Antero-superior approaches in the practice of thoracic surgery.
13. Lung Cancer in Estonia.
14. Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience.
15. Combined approach using uniportal video-assisted thoracoscopic surgery in left tracheal sleeve pneumonectomy.
16. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
17. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.